Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.
ACS Med Chem Lett February 11, 2025 DOI: 10.1021/acsmedchemlett.5c00066 (opens in new tab) via PubMed Central
Summary
AI-generated from the abstractThe text describes novel compounds that act as 5-HT2A agonists, which are being developed for treating mental illness or central nervous system disorders. These compounds target the serotonin 2A receptor, a common site for psychedelic and psychiatric drugs. The work likely involves the design, synthesis, or characterization of these compounds as potential therapeutics, though no specific findings, data, or results are provided in this abstract.
Study at a glance
| Characteristics | Peer reviewed |
|---|
Abstract
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.